Skip to main content
. 2021 Aug 2;11(8):138. doi: 10.1038/s41408-021-00530-3

Fig. 2. Kinetics of NAbs in patients with symptomatic MM compared with age- and sex-matched controls after vaccination with 2 doses of the BNT162b2 or 1 dose of the AZD1222 vaccine.

Fig. 2

Patients with MM had significantly lower NAbs titers on day 22 and on day 50 compared with controls.